

Investing in Oncology



Research Corporation Technologies seeks investable new technologies for diagnosing and treating cancer. These technologies should be developed through the discovery phase to the point where routine preclinical work remains.

Particular areas of interest to RCT include:

- **Anticancer Agents.** RCT seeks pharmaceutically useful small molecules, antibodies and other biologicals that are novel and/or operate to reduce cancer growth by a unique mechanism of action. Such agents could act on cancer cell-signaling, angiogenic, glycolytic, immunologic, apoptotic or protein synthesis/degradation processes. RCT is particularly interested in such agents that have demonstrated significant tumor growth inhibition or even regression in animal models of human tumors. Some evidence of the agent's likely safety should also be apparent.
- **Agents to Treat Cancer-related Morbidities.** Cancer patients do not always succumb to the actions of the primary tumor, but may die from the effects of cancer-induced pathology. RCT is seeking pharmaceutically useful small molecules or biologics that halt or reverse the side effects related to the disease or chemotherapy. Such agents will reduce the effects of cachexia, fatigue, cancer pain, myelosuppression, preneoplastic conditions or alopecia, for example.
- **Cancer Diagnostics.** RCT is seeking cancer novel screening assays performed on body fluids to detect the presence of specific forms of cancer at an early stage of the disease. Such assays will display a high degree of sensitivity and specificity for the cancer type in samples from patients with the disease compared to patients without the disease and patients with possibly confounding disease.

If yours is a a start-up or early-stage company: Through its BioVentures program, RCT invests in technologies that have the potential to become significant biomedical products. Initial financial commitments usually range from several hundred thousand dollars to several million dollars, and we reserve additional funds for the subsequent funding of successful companies. We can also invest management resources if needed.

If you have a new therapeutic: RCT can help facilitate its transition from bench to bedside. We can provide money and management to advance a promising new drug into clinical trials through a variety of business arrangements, including licenses and development partnerships.

If your company or technology meets our criteria and needs further development and commercialization, we would like to hear from you. Please contact us to begin a confidential review of your opportunity.



RESEARCH
CORPORATION
TECHNOLOGIES

5210 East Williams Circle
Suite 240
Tucson, Arizona 85711-4410
Telephone: (520) 748-4400
Fax: (520) 748-0025
Web: www.rctech.com

Contact: Chad W. Souvignier, Ph.D., MBA, at (520) 748-4462 or csouvignier@rctech.com
David A Wiersma, Ph.D., at (520) 748-4442 or dwiersma@rctech.com